62.7 F
New York
Wednesday, October 21, 2020

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Starts New Cannabinoid Study

Must read

Renewed Optimism is Surrounding Sempra Energy (NYSE:SRE)

Sempra Energy (SRE) shares are trading at lower $127.97 and the avg recommendation for the stock is Moderate Buy, while the current analyst price...

Is Now the Time to Invest in Allison Transmission Holdings Inc. (NYSE:ALSN)?

Allison Transmission Holdings Inc. (ALSN) shares are trading at lower $41.06 and the avg recommendation for the stock is Moderate Buy, while the current...

Upwork Inc. (NASDAQ:UPWK) is Gaining Momentum on Earnings Catalyst

Upwork Inc. (UPWK) shares are trading at higher $20.68 and the avg recommendation for the stock is Moderate Buy, while the current analyst price...

DTE Energy Company (NYSE:DTE) on the Path to Ruin

DTE Energy Company (DTE) shares are trading at lower $118.17 and the avg recommendation for the stock is Moderate Buy, while the current analyst...

OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) has had an interesting year so far trading strong from .25 cents to $2.75 in the first quarter. The share price appreciation for OWCP was a bit delayed as investors accumulated other stocks in the cannabis sector, but between February and April shares moved from .60 cents to $2.75, and then back to .60 cents. Unless you are a professional market maker, this price volatility is unwanted, and nearly all cannabis stocks are experiencing volatility on some level. This is no place for the short pocket trader. This is a buy and hold strategy as we get closer to legalization on a federal level and the entry point will be the most important factor.

The company is an Israeli-based research company engaged in the development of cannabinoid-based therapies and today they announced that the Scientific Advisory Team of its wholly-owned Israeli subsidiary, One World Cannabis Ltd. has determined the road map for continuing the Multiple Myeloma study.

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) and the purpose for its next phase of the study, which is based upon the results of earlier in-vitro studies of its unique formula of cannabinoid-based therapies targeting cells, is to investigate the doses and diverse delivery systems. The study is to best determine the most effective dosages and means of delivery for a future planned study on human patients following receipt of regulatory approvals. The Company expects that the continued study will be completed during Q3 of this year.
Subscribe below and we’ll keep you on top of what’s happening before $OWCP stock makes its next move.

Dr. Yehuda Baruch, the Company’s Chief Science Officer and Director of Research and Regulatory Affairs of OWC stated: “After in-depth and extensive review and assessment of the study’s results accumulated so far, OWC’s research committee determined that the medical and scientific accepted multiple myeloma mice model is the best way to progress, compared to other possible known scientific paths. This unique study, which we designed to pursue and secure FDA orphan designation status, will hopefully open ways to improve the quality of life of multiple myeloma patients while at the same time may potentially enhance response to various multiple myeloma treatment regimes.”

The initial OWC study was conducted at the Israeli-renowned Academic Medical Center using three repetitive tests on the effect of OWC’s proprietary cannabis extract with various combination ratios of THC/CBD and pure THC and CBD (50% concentration). The results from the earlier study demonstrated more than 60% malignant cell death. In view of the basic study results, OWCP has begun the development of a unique formulation that includes cannabis extracts for a new delivery system in the form of a cannabis dissoluble tablet to treat multiple myeloma. The cannabis dissoluble tablet will provide physicians with the ability to control and administrate optimal dosage. This can be treated with every multiple myeloma patient and will replace the common usage of smoking medical cannabis today which is not widely accepted by scientists and physicians as smoking, edibles and oil extracts with no meaningful or substantial dosage control.

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP), through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis.

OWCP has similar chart patterns to many in the industry, comparing some of the research driven companies you will find you have a clear division between medical cannabis companies and retail focused stocks focused on dispensaries.

The research division at OWCP is focusing on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions on the medical side of the ledger. The internal consulting division is dedicating help to governments and companies to navigate complex international cannabis regulatory frameworks. This clear division in what they do allows them to fall into the “not touching the plant” (NTP) category in cannabis as investors watch them divide into 2 sub-sectors: (TTP) touch the plant and (NTP) not touch the plant.

From a technical level, we are watching the volume indicator as well as how they hold the recent lows near .50 cents. This level is a significant metric to watch for them, stay tuned here for news about our growing sector of cannabis names. Many of these stocks are finding support as we turn the corner into the reality of legalization on a federal level in the US, and are dividing into two (2) very clear sub-sectors in TTP and NTP. For continuing coverage on shares of $OWCP stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Latest article

Is Now the Time to Invest in SITE Centers Corp. (NYSE:SITC)?

SITE Centers Corp. (SITC) shares are trading at lower $7.19 and the avg recommendation for the stock is Moderate Buy, while the current analyst...

Anheuser-Busch InBev SA/NV (NYSE:BUD) Stock is Soaring, Here is Why

Anheuser-Busch InBev SA/NV (BUD) shares are trading at higher $55.53 and the avg recommendation for the stock is Strong Buy, while the current analyst...

Manulife Financial Corporation (NYSE:MFC) is Holding Steady

Manulife Financial Corporation (MFC) shares are trading at lower $14.02 and the avg recommendation for the stock is Strong Buy, while the current analyst...

Investor Confidence is Falling for Paychex Inc. (NASDAQ:PAYX)

Paychex Inc. (PAYX) shares are trading at lower $81.93 and the avg recommendation for the stock is Moderate Buy, while the current analyst price...

Splunk Inc. (NASDAQ:SPLK) is Gaining Momentum on Earnings Catalyst

Splunk Inc. (SPLK) shares are trading at higher $207.21 and the avg recommendation for the stock is Moderate Buy, while the current analyst price...